Abstract
Extreme weather events are common in high malaria burden areas and likely to increase in severity due to climate change. Yet, data on infection rates following these events and the consequences for disease control programs remain rare. Using data from Madagascar, we estimate high rates of infection in the wake of two major tropical cyclones and show infection rebounds rapidly during gaps in standard interventions. Relative to other control options, recently available malaria vaccines have a longer duration of protection, with the potential to address interruptions in prevention deployment. Evaluating this use, we quantify the reduction in symptomatic infections expected for a range of vaccination scenarios. We find long-lasting interventions such as vaccination are a key mitigation measure against climatic disruptions to disease control.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the CRS SCP4 Multisectoral Malaria Project (BLR, SM, MR), The Falcon Award for Disease Elimination - The Climate Edit by the Global Institute for Disease Elimination (GLIDE) (BLR, MR), The Ren Che Foundation and the AWS Impact Computing Project at the Harvard Data Science Initiative (HDSI) (CDG), The High Meadows Environmental Institute (HMEI) at Princeton University (BLR, GAV, CJEM)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study procedures received approval from the Institutional Review Board (IRB) of the Harvard T.H. Chan School of Public Health (IRB#21-0111), Comite d'Ethique de la Recherche Biomedicale (CERBM) at Ministere de la Sante Publique de Madagascar (No019/MSANP/SG/AMM/CERBM 2021)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Revisions in response to the first round of peer review
Data Availability
All data are available in the main text or the supplementary materials. Data files are available at a github repository: https://github.com/bennyrice/mananjary_cyclone_code
